Canada's Drug Price Watchdog Rethinks Pricing Guidelines to Improve Affordability of, Access to, Prescription Drugs

    June 24, 2016

    Patented Medicine Prices Review Board launches first phase of major consultations to modernize its legal framework

    OTTAWA, ONTARIO - The Patented Medicine Prices Review Board (PMPRB) today launched the first phase of a major consultation initiative that will ultimately change the way the federal government determines whether Canadian patented drug prices are excessive. The PMPRB's regulatory framework will be modernized and simplified to better protect Canadian consumers from excessive patented drug prices in today's rapidly evolving pharmaceutical market.

    Through the Guidelines Modernization Discussion Paper, the PMPRB is seeking to generate an open, informed dialogue with stakeholders and members of the public on areas of the PMPRB's drug pricing guidelines in need of reform as a result of changes to the pharmaceutical environment in Canada and abroad. Feedback in response to the Guidelines Modernization Discussion Paper and the series of questions it puts forward will shape later phases of the consultation process.

    Rethinking the guidelines is an important step toward ensuring the long-term sustainability of the Canadian pharmaceutical system while continuing to improve the accessibility and affordability of prescription drugs.

    Comments must be submitted to the PMPRB in writing by October 24, 2016. All comments will be considered public and will be published on the PMPRB website. Written comments may be submitted by e-mail, letter mail or fax to:

    Patented Medicine Prices Review Board
    (Rethinking the Guidelines)
    Box L40, 333 Laurier Avenue West, Suite 1400
    Ottawa, Ontario K1P 1C1
    Fax: 613-952-7626

    Patented Medicine Prices Review Board